Evidence map›Paper›PMID 32210193›Full record

ArticleViruses2020

Protein Arginine

Hironobu Murakami, Takehiro Suzuki, Kiyoto Tsuchiya, Hiroyuki Gatanaga, Manabu Taura, Eriko Kudo, Seiji Okada, Masami Takei, Kazumichi Kuroda, Tatsuo Yamamoto and 3 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Protein arginine methylation in viral infection and antiviral immunity.International journal of biological sciences · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Hironobu MurakamiViral Infectious Disease Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.ORCID 0000-0002-7560-4445
Takehiro SuzukiBiomolecular Characterization Unit, RIKEN CSRS, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Kiyoto TsuchiyaAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.ORCID 0000-0002-8233-6653
Hiroyuki GatanagaAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
Manabu TauraDivision of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.ORCID 0000-0001-9577-8007
Eriko KudoDivision of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
Seiji OkadaDivision of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.ORCID 0000-0003-3124-5206
Masami TakeiViral Infectious Disease Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Kazumichi KurodaNihon University School of Medicine, 30-1 Oyaguchi, Itabashi, Tokyo 173-8610, Japan.
Tatsuo YamamotoNihon University School of Medicine, 30-1 Oyaguchi, Itabashi, Tokyo 173-8610, Japan.
Kyoji HagiwaraViral Infectious Disease Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Naoshi DohmaeAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
Yoko AidaViral Infectious Disease Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Nihon University · JPKumamoto University · JPNational Center for Global Health and Medicine · JPRIKEN · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current therapies for human immunodeficiency virus type 1 (HIV-1) do not completely eliminate viral reservoirs in cells, such as macrophages. The HIV-1 accessory protein viral protein R (Vpr) promotes virus production in macrophages, and the maintenance of Vpr is essential for HIV-1 replication in these reservoir cells. We identified two novel Vpr-binding proteins, i.e., protein arginine

Indexed as

Host-Pathogen InteractionsVirus ReplicationAmino Acid SequenceCarrier ProteinsCell LineCells, CulturedGene Knockdown TechniquesHIV-1HIV InfectionsHumansMacrophagesProtein-Arginine N-MethyltransferasesProtein Bindingvpr Gene Products, Human Immunodeficiency VirusCarrier ProteinsPRMT5 protein, humanPRMT7 protein, humanProtein-Arginine N-Methyltransferasesvpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1HIV-1macrophagepathogenesisPRMT5PRMT7stabilityvirus productionVprVpr-binding protein

Identifiers

PMID32210193
PMCPMC7150949
OpenAlexW3012801971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.